Publications

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. September 2019

https://pubmed.ncbi.nlm.nih.gov/31535829/

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction. The DEFINE-HF Trial.  September 2019

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042929

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.  October 2021

https://doi.org/10.1038%2Fs41591-021-01536-x

Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 (DARE-19): a randomized, double-blind, placebo-controlled, phase 3 trial.

https://doi.org/10.1016/s2213-8587(21)00180-7

Ticagrelor in Patients with Stable Coronary Disease and Diabetes. Collaborator. September 2019

https://doi.org/10.1056/nejmoa1908077

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomized trial. Collaborator. September 2019.

https://doi.org/10.1016/s0140-6736(19)31887-2

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Collaborator. November 2019.

https://doi.org/10.1056/nejmoa1911303